Please enable JavaScript to continue using this application.

Compare $AVBP vs $CRVS | Chartloom

Compare

$AVBP vs $CRVS

ArriVent BioPharma Inc · Corvus Pharmaceuticals Inc

AVBP

ArriVent BioPharma Inc

CRVS

Corvus Pharmaceuticals Inc

Compare $AVBP vs $CRVS

Comparing ArriVent BioPharma Inc and Corvus Pharmaceuticals Inc

AVBPArriVent BioPharma Inc

CRVSCorvus Pharmaceuticals Inc

AVBPArriVent BioPharma Inc

Market cap

$779M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

18.53x

Rev growth (TTM)

—

YTD performance

-19.6%

52W performance

-19.6%

FCF yield

-19.0%

CRVSCorvus Pharmaceuticals Inc

Market cap

$885M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

43.7%

52W performance

50.3%

FCF yield

-5.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVBP

CRVS

Detailed metrics comparison

AVBP

ArriVent BioPharma Inc

CRVS

Corvus Pharmaceuticals Inc

Market Cap

AVBP$779M

CRVS$885M

Enterprise Value

AVBP$624M

CRVS$866M

Price

AVBP$16.73

CRVS$10.52

P/E Ratio

AVBPN/A

CRVSN/A

P/S Ratio

AVBP0.00x

CRVS0.00x

EV/Sales

AVBP0.00x

CRVS0.00x

EV/EBITDA

AVBP0.00x

CRVS0.00x

P/B Ratio

AVBP3.80x

CRVS4.07x

P/FCF Ratio

AVBPN/A

CRVSN/A

EV/FCF

AVBP-4.22x

CRVS-19.14x

PEG Ratio

AVBPN/A

CRVSN/A

Forward P/E (NTM)

AVBPN/A

CRVSN/A

Forward P/S (NTM)

AVBP18.53x

CRVSN/A

Revenue (TTM)

AVBP$0

CRVS$0

Revenue Growth (YoY)

AVBPN/A

CRVSN/A

Forward Rev Growth

AVBP244.4%

CRVS1220.6%

Gross Margin (TTM)

AVBP0.0%

CRVS0.0%

Operating Margin (TTM)

AVBP0.0%

CRVS0.0%

EBITDA Margin (TTM)

AVBP0.0%

CRVS0.0%

Net Margin (TTM)

AVBP0.0%

CRVS0.0%

FCF Margin (TTM)

AVBPN/A

CRVSN/A

Net Income (TTM)

AVBP$-164M

CRVS$-54M

FCF (TTM)

AVBP$-148M

CRVS$-45M

EPS (TTM)

AVBP-$3.44

CRVS-$0.59

ROE (TTM)

AVBP-5026.0%

CRVS-3615.0%

ROA (TTM)

AVBP-4666.0%

CRVS-3362.0%

ROIC (TTM)

AVBP-5026.0%

CRVS-3615.0%

Cash

AVBP$155M

CRVS$19M

Debt

AVBP$0

CRVS$0

Net Cash/Debt

AVBP$155M

CRVS$19M

Current Ratio (TTM)

AVBP14.16x

CRVS16.16x

Quick Ratio (TTM)

AVBP14.14x

CRVS15.92x

Debt/Equity (TTM)

AVBP0.00x

CRVS0.00x

Debt/Assets (TTM)

AVBP0.0%

CRVS0.0%

Interest Coverage (TTM)

AVBPN/A

CRVSN/A

Net Debt/EBITDA (TTM)

AVBP0.00x

CRVS0.00x

Beta

AVBP1.42

CRVS1.59

52W Performance

AVBP-19.6%

CRVS50.3%

YTD Performance

AVBP-19.6%

CRVS43.7%

% from 52W High

AVBP-53.3%

CRVS-61.0%

% from 52W Low

AVBP47.3%

CRVS64.6%

Asset Turnover (TTM)

AVBP0.00x

CRVS0.00x

FCF Yield (TTM)

AVBP-19.0%

CRVS-5.1%

Earnings Yield (TTM)

AVBP-21.0%

CRVS-6.1%

Dividend Yield (TTM)

AVBPN/A

CRVSN/A

Rule of 40

AVBP0.0

CRVS0.0

EV/GP/RG

AVBPN/A

CRVSN/A

Ticker research

View AVBP research View CRVS research

Metric	AVBP ArriVent BioPharma Inc	CRVS Corvus Pharmaceuticals Inc
Market & Valuation
Market Cap	$779M	$885M
Enterprise Value	$624M	$866M
Price	$16.73	$10.52
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.80x	4.07x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.22x	-19.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	18.53x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	244.4%	1220.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-164M	$-54M
FCF (TTM)	$-148M	$-45M
EPS (TTM)	-$3.44	-$0.59
ROE (TTM)	-5026.0%	-3615.0%
ROA (TTM)	-4666.0%	-3362.0%
ROIC (TTM)	-5026.0%	-3615.0%
Financial Health
Cash	$155M	$19M
Debt	$0	$0
Net Cash/Debt	$155M	$19M
Current Ratio (TTM)	14.16x	16.16x
Quick Ratio (TTM)	14.14x	15.92x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.42	1.59
52W Performance	-19.6%	50.3%
YTD Performance	-19.6%	43.7%
% from 52W High	-53.3%	-61.0%
% from 52W Low	47.3%	64.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-19.0%	-5.1%
Earnings Yield (TTM)	-21.0%	-6.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AVBP research	View CRVS research

Valuation

P/S Ratio

AVBP

0.00x

CRVS

0.00x

EV/FCF

CRVS

-19.14x

AVBP

-4.22x

Growth & revenue

Forward Revenue Growth

CRVS

1220.6%

AVBP

244.4%

Profitability & performance

Gross Margin

AVBP

0.0%

CRVS

0.0%

ROE

CRVS

-3615.0%

AVBP

-5026.0%

FCF Yield %

CRVS

-5.1%

AVBP

-19.0%

52-Week Performance

CRVS

50.3%

AVBP

-19.6%

Detailed metrics comparison

AVBP

ArriVent BioPharma Inc

CRVS

Corvus Pharmaceuticals Inc

Market Cap

AVBP$779M

CRVS$885M

Enterprise Value

AVBP$624M

CRVS$866M

Price

AVBP$16.73

CRVS$10.52

P/E Ratio

AVBPN/A

CRVSN/A

P/S Ratio

AVBP0.00x

CRVS0.00x

EV/Sales

AVBP0.00x

CRVS0.00x

EV/EBITDA

AVBP0.00x

CRVS0.00x

P/B Ratio

AVBP3.80x

CRVS4.07x

P/FCF Ratio

AVBPN/A

CRVSN/A

EV/FCF

AVBP-4.22x

CRVS-19.14x

PEG Ratio

AVBPN/A

CRVSN/A

Forward P/E (NTM)

AVBPN/A

CRVSN/A

Forward P/S (NTM)

AVBP18.53x

CRVSN/A

Revenue (TTM)

AVBP$0

CRVS$0

Revenue Growth (YoY)

AVBPN/A

CRVSN/A

Forward Rev Growth

AVBP244.4%

CRVS1220.6%

Gross Margin (TTM)

AVBP0.0%

CRVS0.0%

Operating Margin (TTM)

AVBP0.0%

CRVS0.0%

EBITDA Margin (TTM)

AVBP0.0%

CRVS0.0%

Net Margin (TTM)

AVBP0.0%

CRVS0.0%

FCF Margin (TTM)

AVBPN/A

CRVSN/A

Net Income (TTM)

AVBP$-164M

CRVS$-54M

FCF (TTM)

AVBP$-148M

CRVS$-45M

EPS (TTM)

AVBP-$3.44

CRVS-$0.59

ROE (TTM)

AVBP-5026.0%

CRVS-3615.0%

ROA (TTM)

AVBP-4666.0%

CRVS-3362.0%

ROIC (TTM)

AVBP-5026.0%

CRVS-3615.0%

Cash

AVBP$155M

CRVS$19M

Debt

AVBP$0

CRVS$0

Net Cash/Debt

AVBP$155M

CRVS$19M

Current Ratio (TTM)

AVBP14.16x

CRVS16.16x

Quick Ratio (TTM)

AVBP14.14x

CRVS15.92x

Debt/Equity (TTM)

AVBP0.00x

CRVS0.00x

Debt/Assets (TTM)

AVBP0.0%

CRVS0.0%

Interest Coverage (TTM)

AVBPN/A

CRVSN/A

Net Debt/EBITDA (TTM)

AVBP0.00x

CRVS0.00x

Beta

AVBP1.42

CRVS1.59

52W Performance

AVBP-19.6%

CRVS50.3%

YTD Performance

AVBP-19.6%

CRVS43.7%

% from 52W High

AVBP-53.3%

CRVS-61.0%

% from 52W Low

AVBP47.3%

CRVS64.6%

Asset Turnover (TTM)

AVBP0.00x

CRVS0.00x

FCF Yield (TTM)

AVBP-19.0%

CRVS-5.1%

Earnings Yield (TTM)

AVBP-21.0%

CRVS-6.1%

Dividend Yield (TTM)

AVBPN/A

CRVSN/A

Rule of 40

AVBP0.0

CRVS0.0

EV/GP/RG

AVBPN/A

CRVSN/A

Ticker research

View AVBP research View CRVS research

Metric	AVBP ArriVent BioPharma Inc	CRVS Corvus Pharmaceuticals Inc
Market & Valuation
Market Cap	$779M	$885M
Enterprise Value	$624M	$866M
Price	$16.73	$10.52
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.80x	4.07x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.22x	-19.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	18.53x	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	244.4%	1220.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-164M	$-54M
FCF (TTM)	$-148M	$-45M
EPS (TTM)	-$3.44	-$0.59
ROE (TTM)	-5026.0%	-3615.0%
ROA (TTM)	-4666.0%	-3362.0%
ROIC (TTM)	-5026.0%	-3615.0%
Financial Health
Cash	$155M	$19M
Debt	$0	$0
Net Cash/Debt	$155M	$19M
Current Ratio (TTM)	14.16x	16.16x
Quick Ratio (TTM)	14.14x	15.92x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.42	1.59
52W Performance	-19.6%	50.3%
YTD Performance	-19.6%	43.7%
% from 52W High	-53.3%	-61.0%
% from 52W Low	47.3%	64.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-19.0%	-5.1%
Earnings Yield (TTM)	-21.0%	-6.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View AVBP research	View CRVS research